Science News
from research organizations

New Drug Combination Shows Promise For African Sleeping Sickness

Date:
November 19, 2007
Source:
Public Library of Science
Summary:
A small clinical trial in Uganda, conducted within a long-established Medecins Sans Frontieres treatment program for African sleeping sickness, has found that a new combination treatment using the drugs nifurtimox and eflornithine holds promise and deserves further evaluation. Despite the low sample size, the findings were promising: no cases of treatment failure, no treatment terminations, and no HAT- or treatment-related deaths.
Share:
FULL STORY

A small clinical trial in Uganda, conducted within a long-established Médecins Sans Frontières (MSF) treatment program for African sleeping sickness, has found that a new combination treatment using the drugs nifurtimox and eflornithine holds promise and deserves further evaluation.

The parasitic disease African sleeping sickness (human African trypanosomiasis, or HAT) threatens millions across remote and conflict-affected regions of sub-Saharan Africa, and causes about 15 000 reported cases every year. Without treatment, HAT progresses from stage 1, infection of the blood and lymph, to stage 2, invasion of the central nervous system, and then to death.

There are few drugs available for treating stage 2. The historical mainstay, melarsoprol, is highly toxic and is ineffective in some areas due to parasite resistance. Eflornithine is the only viable alternative, already established as safe and efficacious, but it is difficult to administer--it is given intravenously and requires 24 hour nursing care, placing an additional workload on the already fragile health systems in HAT-endemic countries.

The new trial, by Gerardo Priotto (Epicentre, Paris, France) and colleagues at MSF and Epicentre, reports on a series of 48 patients treated with a novel combination of nifurtimox (a drug registered for Chagas disease) and eflornithine. Seventeen patients were recruited as part of a terminated randomized trial (previously published in PLoS Clinical Trials) and 31 in a subsequent case series study.

Despite the low sample size, the findings were promising: no cases of treatment failure, no treatment terminations, and no HAT- or treatment-related deaths.

"Nifurtimox plus eflornithine may be the best treatment hope for stage 2 HAT patients in the next decade, while new drugs are developed," say the authors. "A larger, multi-centric trial of the combination is ongoing."

Citation: Checchi F, Piola P, Ayikoru H, Thomas F, Legros D, et al. (2007) Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series. PLoS Negl Trop Dis 1(2): e64. doi:10.1371/journal.pntd.0000064


Story Source:

Materials provided by Public Library of Science. Note: Content may be edited for style and length.


Cite This Page:

Public Library of Science. "New Drug Combination Shows Promise For African Sleeping Sickness." ScienceDaily. ScienceDaily, 19 November 2007. <www.sciencedaily.com/releases/2007/11/071107074340.htm>.
Public Library of Science. (2007, November 19). New Drug Combination Shows Promise For African Sleeping Sickness. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2007/11/071107074340.htm
Public Library of Science. "New Drug Combination Shows Promise For African Sleeping Sickness." ScienceDaily. www.sciencedaily.com/releases/2007/11/071107074340.htm (accessed May 23, 2017).

RELATED STORIES